Dosing and Administration for Dialysis and Non-Dialysis Patients | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
PulmCrit - Sodium Zirconium Cyclosilicate for urgent treatment of hyperkalemia?
PDF) The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure
Drug Trials Snapshots: LOKELMA | FDA
Table 4 from Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review | Semantic Scholar
NephMadness 2020: Hyperkalemia Region – AJKD Blog
Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Singapore
Dosing and Administration for Dialysis and Non-Dialysis Patients | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
Drug Trials Snapshots: LOKELMA | FDA
Lokelma Vs Kayexalate Which is More Effective? - Public Health
Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Singapore
Lokelma sodium zirconium cyclosilicate treatment for hyperkalaemia
The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure | BMC Nephrology | Full Text
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
Drug Trials Snapshots: LOKELMA | FDA
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
Hyperkalemia Treatment Lokelma Gets FDA Approval - MPR
Another small step forward for Lokelma with UK reimbursement easing
Lokelma sodium zirconium cyclosilicate treatment for hyperkalaemia
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
JCM | Free Full-Text | Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis | HTML
